Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 02/06/2026

    New approach to prevent treatment-induced leukemia Protective mechanism against DNA damage caused by chemotherapy and radiotherapy discovered

    In rare cases, cancer treatments can cause serious long-term effects. These include so-called secondary leukemias. This form of blood cancer can develop when chemotherapy or radiotherapy damages the genetic material of healthy cells. A research team led by a scientist from Ulm has now discovered a molecular protective mechanism against such genomic damage: a peptide.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-prevent-treatment-induced-leukemia-protective-mechanism-against-dna-damage-caused-chemotherapy-and-radiotherapy-dis
  • Press release - 01/06/2026

    Excellent Doctoral Training Enters Second Funding Phase: Medical Faculties at Heidelberg University Continue Successful Graduate Program in the field of Immunology

    The German Research Foundation (DFG) funds continuation of Research Training Group (RTG) 2727 “Checkpoints of Innate Immunity in Cancer and Tissue Damage”, with around €5,8 million.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/excellent-doctoral-training-enters-second-funding-phase-medical-faculties-heidelberg-university-continue-successful-graduate-pro
  • Press release - 10/06/2026

    AI Diagnoses Brain Tumors in Minutes Instead of Weeks

    Experts in Heidelberg have developed an AI system that can classify brain tumors with unprecedented accuracy using standard microscopic tissue sections. Using digitized standard stains, the system identifies more than 100 molecular subtypes of central nervous system tumors, delivers results within minutes, and could accelerate the diagnosis of brain tumors worldwide.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ai-diagnoses-brain-tumors-minutes-instead-weeks
  • Press release - 10/06/2026

    NEURA Robotics announces record series C of up to $1,4 Billion to accelerate the world's leading physical AI Platform

    NEURA Robotics (“NEURA”), the pioneer in cognitive robotics and creator of the Neuraverse, today announced a landmark Series C financing with a total round size of up to $1.4 billion to accelerate its mission of building the world’s leading Physical AI platform. The financing brings together global leaders across AI, robotics, compute, manufacturing and industrial infrastructure.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/neura-robotics-announces-record-series-c-1-dollars-4-cents-billion-accelerate-worlds-leading-physical-ai-platform
  • Press release - 01/06/2026

    More precise therapeutic agents for neuropsychiatry: The NMI is helping to unravel complex receptor mechanisms

    How can effective treatments for neuropsychiatric disorders be developed without having to accept unwanted side effects? Researchers at the NMI have made an important contribution to this field. In their recent paper, “NMDA receptor subtype differential affinity as a key enabler for precision neuropsychiatry,” they demonstrate how specifically targeting subunits of the NMDA receptor opens up new avenues for safer medications.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/more-precise-therapeutic-agents-neuropsychiatry-nmi-helping-unravel-complex-receptor-mechanisms
  • Press release - 12/06/2026

    The Heidelberg and Mannheim University Hospitals consortium has taken first place in the Stern hospital rankings

    For the first time in 14 years, there has been a change at the top of the hospital rankings, which are published annually by the MINQ Institute in collaboration with Stern. In its very first year of existence, the Heidelberg and Mannheim University Hospitals Consortium has taken first place.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-and-mannheim-university-hospitals-consortium-has-taken-first-place-stern-hospital-rankings
  • Funding

    Wittenstein Biointelligence Award

    Competition, Funded by: Wittenstein Foundation, sb_search.searchresult.label.programSubmissionDate: 31/07/2026
    https://www.gesundheitsindustrie-bw.de/en/database/funding/wittenstein-biointelligence-award-en
  • Press release - 12/06/2026

    The University of Freiburg and Nagoya University agree on a joint doctoral programme

    The University of Freiburg and Nagoya University are strengthening their strategic partnership through a joint doctoral programme and the Nagoya University Global Campus, which serves as a permanently staffed representative office in Freiburg.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/university-freiburg-and-nagoya-university-agree-joint-doctoral-programme
  • Press release - 10/06/2026

    Can Aztekin receives 2026 Schering Young Investigator Award

    This year’s Schering Young Investigator Award has been awarded to Can Aztekin, a Max-Planck-Research Group Leader at the Friedrich Miescher Laboratory of the Max Planck Society in Tübingen, to recognize his significant work in the field of regenerative biology.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/can-aztekin-receives-2026-schering-young-investigator-award

Page 40 / 40

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 36
  • 37
  • 38
  • 39
  • 40
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2026
Website address: https://www.gesundheitsindustrie-bw.de/en/search